Immix Biopharma

IMMX Rare disease Lead: Phase 1 2 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-25

Catalyst timeline

NXC-201 Ph2 toplineSep 2026NXC-201 Ph2 topline, Sep 2026, thesis-defining
NXC-201 BLA filingLate 2026NXC-201 BLA filing, Late 2026, notable
NXC-201 corporate updateSep 2026NXC-201 corporate update, Sep 2026, routine
NXC-201 commercial launch1H 2027NXC-201 commercial launch, 1H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (1 active programs)

NXC-201

Cell Target: BCMA

Relapsed/Refractory AL Amyloidosis Phase 1 Phase1/2 trial Memorial Sloan Kettering Cancer Center NCT06097832

Technology platforms

N-GENIUS · Hadasit

Cell engineering platform with EXPAND technology and COBRA binder scaffold generation; produces CAR-T candidates targeting BCMA and other targets for hematologic, neurologic, rheumatologic, vascular and other serious diseases

Targets: BCMA

N-GENIUS

Proprietary CAR-T cell therapy development platform that produced NXC-201, a next-generation CAR-T designed to treat AL Amyloidosis and other serious diseases

Biotech Distilled coverage (2)

2026-05-21 UPDATE: Immix Biopharma (IMMX) — The 95% CR Lands, and the Dilution Gap Closes Before It Opens 🔒 Paid
2026-05-12 Immix Biopharma (IMMX) - Scientific Deep Dive for NXC-201 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.